Review/NN
on/IN
Molecular/JJ
and/CC
Chemopreventive/JJ
Potential/JJ
of/IN
Nimbolide/NN
in/IN
Cancer/NN
./.
====================
Cancer/NN
is/VBZ
the/DT
most/JJS
dreaded/VBD
disease/NN
in/IN
human/JJ
and/CC
also/RB
major/JJ
health/NN
problem/NN
worldwide/NN
./.
====================
Despite/IN
its/PRP$
high/JJ
occurrence/NN
,/,
the/DT
exact/JJ
molecular/JJ
mechanisms/NNS
of/IN
the/DT
development/NN
and/CC
progression/NN
are/VBP
not/RB
fully/RB
understood/VBN
./.
====================
The/DT
existing/VBG
cancer/NN
therapy/NN
based/VBN
on/IN
allopathic/JJ
medicine/NN
is/VBZ
expensive/JJ
,/,
exhibits/VBZ
side/JJ
effects/NNS
;/:
and/CC
may/MD
also/RB
alter/VBP
the/DT
normal/JJ
functioning/VBG
of/IN
genes/NNS
./.
====================
Thus/RB
,/,
a/DT
non-toxic/JJ
and/CC
effective/JJ
mode/NN
of/IN
treatment/NN
is/VBZ
needed/VBN
to/TO
control/VB
cancer/NN
development/NN
and/CC
progression/NN
./.
====================
Some/DT
medicinal/JJ
plants/NNS
offer/VBP
a/DT
safe/JJ
,/,
effective/JJ
and/CC
affordable/JJ
remedy/NN
to/TO
control/VB
the/DT
cancer/NN
progression/NN
./.
====================
Nimbolide/NN
,/,
a/DT
limnoid/JJ
derived/VBN
from/IN
the/DT
neem/NN
(/(
Azadirachta/NN
indica/NN
)/)
leaves/VBZ
and/CC
flowers/NNS
of/IN
neem/NN
,/,
is/VBZ
widely/RB
used/VBN
in/IN
traditional/JJ
medical/JJ
practices/NNS
for/IN
treating/VBG
various/JJ
human/JJ
diseases/NNS
./.
====================
Nimbolide/NN
exhibits/VBZ
several/JJ
pharmacological/JJ
effects/NNS
among/IN
which/WDT
its/PRP$
anticancer/JJ
activity/NN
is/VBZ
the/DT
most/JJS
promising/VBG
./.
====================
The/DT
previous/JJ
studies/NNS
carried/VBD
out/RP
over/IN
the/DT
decades/NNS
have/VBP
shown/VBN
that/IN
nimbolide/NN
inhibits/VBZ
cell/NN
proliferation/NN
and/CC
metastasis/NN
of/IN
cancer/NN
cells/NNS
./.
====================
This/DT
review/NN
highlights/VBZ
the/DT
current/JJ
knowledge/NN
on/IN
the/DT
molecular/JJ
targets/NNS
that/DT
contribute/VBP
to/TO
the/DT
observed/VBN
anticancer/JJ
activity/NN
of/IN
nimbolide/NN
related/JJ
to/TO
induction/NN
of/IN
apoptosis/NN
and/CC
cell/NN
cycle/NN
arrest/NN
;/:
and/CC
inhibition/NN
of/IN
signaling/VBG
pathways/NNS
related/JJ
to/TO
cancer/NN
progression/NN
./.
====================
Cancer/NN
is/VBZ
the/DT
most/JJS
dangerous/JJ
disease/NN
of/IN
human/JJ
and/CC
a/DT
major/JJ
health/NN
problem/NN
worldwide/NN
[/(
1/CD
]/)
./.
====================
Preclinical/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
cancer/NN
is/VBZ
a/DT
large/JJ
group/NN
of/IN
diseases/NNS
characterized/VBN
by/IN
the/DT
uncontrolled/JJ
cell/NN
growth/NN
and/CC
spread/VBN
of/IN
abnormal/JJ
cells/NNS
./.
====================
Over/RB
the/DT
past/NN
quarter/RB
of/IN
a/DT
century/JJ
,/,
an/DT
outstanding/JJ
progress/VBP
in/IN
understanding/VBG
of/IN
the/DT
proteins/NNS
involved/VBN
in/IN
cancer/NN
progression/NN
has/VBZ
grown/VBN
,/,
providing/VBG
chances/NNS
for/IN
identifying/VBG
new/JJ
targets/NNS
for/IN
anti-cancer/JJ
therapy/NN
[/(
2/CD
,/,
3/CD
]/)
./.
====================
Present/JJ
modes/NNS
of/IN
treatment/NN
based/VBN
on/IN
synthetic/JJ
drugs/NNS
have/VBP
limited/VBN
potential/JJ
,/,
because/IN
they/PRP
are/VBP
toxic/JJ
and/CC
expensive/JJ
and/CC
also/RB
alter/VBP
cell/NN
signaling/NN
pathways/NNS
./.
====================
Natural/JJ
drugs/NNS
that/WDT
are/VBP
safe/JJ
,/,
affordable/JJ
,/,
and/CC
effective/JJ
are/VBP
needed/VBN
to/TO
control/VB
cancer/NN
development/NN
and/CC
progression/NN
./.
====================
Natural/JJ
products/NNS
have/VBP
been/VBN
used/VBN
for/IN
thousands/NNS
of/IN
years/NNS
in/IN
the/DT
management/NN
of/IN
several/JJ
diseases/NNS
including/VBG
various/JJ
types/NNS
of/IN
cancer/NN
[/(
4/CD
]/)
./.
====================
Nimbolide/NN
was/VBD
first/JJ
derived/VBN
from/IN
the/DT
leaves/NNS
and/CC
flowers/NNS
of/IN
neem/NN
./.
====================
Neem/RB
(/(
Azadirachta/NN
indica/NN
)/)
,/,
is/VBZ
a/DT
traditional/JJ
medicinal/JJ
plant/JJ
of/IN
the/DT
Meliaceae/NN
family/NN
widely/RB
distributed/VBN
in/IN
Asia/NN
,/,
Africa/NNP
and/CC
other/JJ
tropical/JJ
parts/NNS
of/IN
the/DT
world/NN
./.
====================
All/DT
parts/NNS
of/IN
the/DT
neem/NN
tree/CD
offer/VBP
amazing/VBG
potential/JJ
for/IN
medicinal/JJ
,/,
agricultural/JJ
and/CC
industrial/JJ
exploitation/NN
and/CC
have/VBP
been/VBN
evaluated/VBN
for/IN
antiinflammatory/JJ
,/,
antipyretic/JJ
,/,
antihistamine/JJ
,/,
antifungal/JJ
,/,
antitubercular/JJ
,/,
antiprotozoal/JJ
,/,
vasodilatory/JJ
,/,
antimalarial/JJ
,/,
diuretic/JJ
,/,
spermicidal/JJ
,/,
antiarthritic/JJ
,/,
insect/NN
repellent/JJ
,/,
antifeedant/JJ
,/,
and/CC
antihormonal/JJ
activities/NNS
[/(
5/CD
]/)
./.
====================
Studies/NNS
of/IN
extracts/NNS
from/IN
all/DT
major/JJ
parts/NNS
of/IN
neem/NN
plant/JJ
including/VBG
the/DT
leaves/NNS
,/,
flowers/NNS
,/,
fruits/VBZ
,/,
and/CC
seeds/VBZ
,/,
have/VBP
shown/VBN
promising/VBG
chemopreventive/JJ
and/CC
therapeutic/JJ
effects/NNS
in/IN
pre-clinical/JJ
research/NN
[/(
6/CD
]/)
./.
====================
Extracts/NNS
of/IN
neem/NN
leaf/NN
have/VBP
been/VBN
reported/VBN
to/TO
be/VB
non-toxic/JJ
and/CC
non-mutagenic/JJ
and/CC
are/VBP
found/VBN
to/TO
possess/VB
immunomodulatory/JJ
as/IN
well/RB
as/IN
anti-inflammatory/JJ
and/CC
anticarcinogenic/JJ
properties/NNS
[/(
7/CD
]/)
./.
====================
There/EX
are/VBP
many/JJ
studies/NNS
showing/VBG
the/DT
ethanolic/JJ
extract/NN
of/IN
neem/NN
leaves/VBZ
to/TO
possess/VB
anticancer/JJ
activity/NN
./.
====================
Ethanolic/JJ
neem/NN
leaf/NN
extract/NN
(/(
ENLE/NN
)/)
exhibited/VBD
anticancer/JJ
activity/NN
against/IN
N-methyl-N'-nitro-N-nitrosoguanidine-induced/JJ
oxidative/JJ
stress/NN
and/CC
gastric/JJ
carcinogenesis/NN
[/(
8/CD
]/)
./.
====================
ENLE/NN
induces/VBZ
apoptosis/NN
in/IN
a/DT
prostate/NN
cancer/NN
cell/NN
line/NN
(/(
PC-3/NN
)/)
by/IN
up-regulating/VBG
the/DT
pro-apoptotic/JJ
protein/NN
Bax/NN
and/CC
decreasing/VBG
the/DT
level/NN
of/IN
Bcl-2/NN
protein/NN
resulting/VBG
in/IN
DNA/NN
fragmentation/NN
in/IN
prostate/NN
cancer/NN
cells/NNS
[/(
9/CD
,/,
10/CD
]/)
./.
====================
Many/JJ
bioactive/JJ
compounds/NNS
are/VBP
isolated/VBN
from/IN
this/DT
plant/JJ
among/IN
which/WDT
,/,
nimbolide/NN
belongs/VBZ
to/TO
the/DT
limonoid/JJ
group/NN
./.
====================
It/PRP
is/VBZ
the/DT
major/JJ
component/NN
of/IN
the/DT
leaves/NNS
of/IN
A./NNP
indica/NN
./.
====================
Nimbolide/NN
(/(
5,7,4'-trihydroxy-3',5'-diprenylflavanone/CD
)/)
,/,
is/VBZ
a/DT
tetranortriterpenoid/JJ
with/IN
a/DT
,/,
β-unsaturated/VBN
system/NN
and/CC
δ-lactonic/JJ
ring/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
[/(
11/CD
]/)
./.
====================
It/PRP
has/VBZ
been/VBN
shown/VBN
to/TO
exhibit/VB
numerous/JJ
types/NNS
of/IN
biological/JJ
activities/NNS
,/,
including/VBG
,/,
anti-malarial/JJ
[/(
12/CD
]/)
,/,
anti-bacterial/JJ
activity/NN
[/(
13/CD
]/)
,/,
anti-feedent/JJ
,/,
[/(
14/CD
]/)
and/CC
anticancer/JJ
activities/NNS
[/(
15/CD
,/,
16/CD
,/,
17/CD
,/,
18/CD
,/,
19/CD
]/)
./.
====================
Literature/JJ
evidence/NN
reveals/VBZ
that/IN
α/VBP
,/,
β-unsaturated/VBN
ketone/NN
structural/JJ
element/NN
is/VBZ
responsible/JJ
for/IN
the/DT
anticancer/JJ
activity/NN
of/IN
nimbolide/NN
[/(
20/CD
,/,
21/CD
]/)
./.
====================
Cancers/NNS
are/VBP
abnormal/JJ
cell/NN
growth/NN
caused/VBD
by/IN
genomic/JJ
modification/NN
./.
====================
So/RB
,/,
any/DT
agent/NN
that/WDT
has/VBZ
anti-cancer/JJ
activity/NN
either/CC
protects/VBZ
genetic/JJ
material/NN
from/IN
alterations/NNS
or/CC
kills/NNS
the/DT
genetically/RB
altered/JJ
cancer/NN
cells/NNS
./.
====================
The/DT
active/JJ
component/NN
nimbolide/NN
from/IN
neem/NN
acts/VBZ
on/IN
cancer/NN
cells/NNS
and/CC
kill/VBP
them/PRP
by/IN
altering/VBG
the/DT
several/JJ
molecular/JJ
pathways/NNS
./.
====================
The/DT
cytotoxicity/NN
of/IN
nimbolide/NN
has/VBZ
been/VBN
widely/RB
studied/VBN
over/IN
the/DT
last/JJ
several/JJ
years/NNS
in/IN
a/DT
large/JJ
variety/NN
of/IN
cancer/NN
cell/NN
lines/NNS
[/(
22/CD
]/)
./.
====================
It/PRP
was/VBD
reported/VBN
recently/RB
that/IN
nimbolide/NN
inhibited/VBD
cancer/NN
progression/NN
by/IN
influencing/VBG
multiple/JJ
mechanisms/NNS
,/,
including/VBG
prevention/NN
of/IN
procarcinogen/NN
activation/NN
and/CC
oxidative/JJ
DNA/NN
damage/NN
,/,
upregulation/NN
of/IN
antioxidant/JJ
and/CC
induction/NN
of/IN
apoptosis/NN
,/,
inhibition/NN
of/IN
tumor/NN
cell/NN
proliferation/NN
,/,
invasion/NN
,/,
angiogenesis/NN
,/,
and/CC
metastasis/NN
[/(
19/CD
,/,
23/CD
,/,
24/CD
,/,
25/CD
,/,
26/CD
]/)
./.
====================
The/DT
potential/JJ
mechanisms/NNS
of/IN
cancer/NN
prevention/NN
by/IN
nimbolide/NN
are/VBP
described/VBN
below/IN
and/CC
summarized/VBD
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
Tumorigenesis/NN
and/CC
cancer/NN
progression/NN
are/VBP
thought/VBN
to/TO
be/VB
the/DT
result/NN
of/IN
some/DT
changes/NNS
in/IN
different/JJ
types/NNS
of/IN
genetic/JJ
pathways/NNS
[/(
27/CD
,/,
28/CD
]/)
./.
====================
Nimbolide/NN
,/,
a/DT
chief/JJ
constituent/NN
of/IN
neem/NN
,/,
shows/VBZ
a/DT
vital/JJ
role/NN
in/IN
cancer/NN
prevention/NN
and/CC
treatment/NN
through/IN
the/DT
modulation/NN
of/IN
various/JJ
biological/JJ
activities/NNS
,/,
including/VBG
molecular/JJ
cascades/NNS
./.
====================
However/RB
,/,
understanding/VBG
the/DT
mechanism/NN
of/IN
action/NN
of/IN
nimbolide/NN
in/IN
the/DT
activation/NN
or/CC
inactivation/NN
of/IN
genetic/JJ
pathways/NNS
will/MD
provide/VB
significant/JJ
information/NN
to/TO
develop/VB
therapeutic/JJ
approaches/NNS
to/TO
manage/VB
various/JJ
types/NNS
of/IN
cancers/NNS
./.
====================
Nimbolide/NN
induces/VBZ
in/IN
vitro/FW
cytotoxic/JJ
activity/NN
against/IN
human/JJ
cancer/NN
cell/NN
lines/NNS
[/(
20/CD
]/)
./.
====================
Nimbolide/NN
decreased/VBD
cell/NN
viability/NN
,/,
with/IN
an/DT
IC50/NN
ranging/VBG
from/IN
4/CD
to/TO
10/CD
µM/NN
and/CC
averaging/VBG
6/CD
µM/NN
for/IN
the/DT
neuroblastoma/NN
(/(
NE-115/CD
)/)
and/CC
osteosarcoma/NN
(/(
143B/NN
)/)
cell/NN
lines/NNS
[/(
15/CD
]/)
./.
====================
Sastry/NN
et/FW
al/JJ
./.
====================
[/(
21/CD
]/)
have/VBP
tested/VBN
the/DT
in/FW
vitro/FW
cytotoxicity/NN
of/IN
nimbolide/NN
against/IN
a/DT
panel/NN
of/IN
human/JJ
cancer/NN
cell/NN
lines/NNS
./.
====================
Treatment/NN
of/IN
cells/NNS
with/IN
0.5-5.0/CD
µM/NN
nimbolide/NN
resulted/VBD
in/IN
growth/NN
inhibition/NN
of/IN
the/DT
U937/NN
,/,
HL-60/NN
,/,
THP1/NN
,/,
and/CC
B16/NN
cell/NN
lines/NNS
./.
====================
It/PRP
has/VBZ
been/VBN
shown/VBN
to/TO
interfere/VB
with/IN
the/DT
expression/NN
of/IN
cell/NN
survival/NN
proteins/NNS
(/(
Bcl-2/NN
,/,
Bcl-xL/NN
,/,
IAP-1/NN
,/,
and/CC
IAP-2/NN
)/)
,/,
proliferation/NN
(/(
cyclin/NN
D1/NN
)/)
,/,
invasion/NN
(/(
matrix/NN
metalloproteinase/NN
[/(
MMP/NN
]/)
-9/CD
)/)
,/,
and/CC
angiogenesis/NN
(/(
vascular/JJ
endothelial/JJ
growth/NN
factor/NN
[/(
VEGF/NN
]/)
)/)
by/IN
inhibiting/VBG
inhibitor/NN
of/IN
κb/JJ
(/(
Iκb/NNP
)/)
kinase/NN
(/(
IKK/NN
)/)
/nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-κB/NN
)/)
[/(
16/CD
]/)
./.
====================
Nimbolide/NN
treatment/NN
to/TO
human/JJ
colon/NN
carcinoma/NN
(/(
HT-29/NN
)/)
cells/NNS
at/IN
2.5-10/CD
µM/NN
resulted/VBD
in/IN
moderate/JJ
to/TO
very/RB
strong/JJ
growth/NN
inhibition/NN
[/(
29/CD
]/)
./.
====================
Nimbolide/DT
significantly/RB
inhibited/VBD
cell/NN
viability/NN
,/,
with/IN
IC50/NN
values/NNS
of/IN
4.0/CD
µM/NN
and/CC
2.7/CD
µM/NN
for/IN
24/CD
and/CC
48/CD
h/NN
,/,
respectively/RB
,/,
in/IN
MCF-7/NN
cells/NNS
and/CC
6.0/CD
µM/NN
and/CC
3.2/CD
µM/NN
for/IN
24/CD
and/CC
48/CD
h/NN
,/,
respectively/RB
,/,
in/IN
MDA-MB-231/NN
cells/NNS
[/(
30/CD
]/)
./.
====================
The/DT
insulin-like/JJ
growth/NN
factor/NN
(/(
IGF/NN
)/)
system/NN
is/VBZ
involved/VBN
in/IN
the/DT
proliferation/NN
,/,
survival/NN
,/,
and/CC
migration/NN
of/IN
tumor/NN
cells/NNS
./.
====================
IGF-I/NN
receptor/NN
(/(
IGF-IR/NN
)/)
is/VBZ
a/DT
receptor/NN
tyrosine/NN
kinase/NN
that/WDT
is/VBZ
overexpressed/VBN
in/IN
about/RB
70/CD
%/NN
of/IN
breast/NN
cancers/NNS
[/(
31/CD
,/,
32/CD
]/)
./.
====================
It/PRP
is/VBZ
established/VBN
that/IN
the/DT
consequences/NNS
of/IN
IGF-IR/NN
activation/NN
by/IN
its/PRP$
ligands/NNS
result/NN
in/IN
the/DT
recruitment/NN
of/IN
major/JJ
adapter/NN
signaling/NN
proteins/NNS
,/,
such/JJ
as/IN
src/collagen/NN
homology/NN
proteins/NNS
,/,
which/WDT
lead/VBP
to/TO
interaction/NN
with/IN
Grb2/Sos/NN
[/(
33/CD
]/)
./.
====================
Recruitment/JJ
of/IN
these/DT
molecules/NNS
activates/VBZ
two/CD
distinct/JJ
signal/NN
transduction/NN
pathways/NNS
./.
====================
One/CD
pathway/NN
activates/VBZ
Ras/NN
,/,
Raf/NN
,/,
and/CC
mitogen-activated/JJ
protein/NN
kinase/NN
(/(
MAPK/NN
)/)
,/,
resulting/VBG
in/IN
the/DT
transcription/NN
of/IN
genes/NNS
that/WDT
drive/VBP
proliferation/NN
,/,
and/CC
the/DT
other/JJ
pathway/NN
involves/VBZ
phosphoinositide/NN
3-kinase/NN
(/(
PI3K/NN
)/)
/Akt/NN
,/,
which/WDT
are/VBP
responsible/JJ
for/IN
cell/NN
survival/NN
and/CC
anti-apoptotic/JJ
signal/NN
transduction/NN
[/(
34/CD
]/)
./.
====================
Downregulation/NN
of/IN
these/DT
molecules/NNS
will/MD
give/VB
rise/NN
to/TO
inhibition/NN
of/IN
cell/NN
survival/NN
,/,
invasion/NN
,/,
and/CC
induction/NN
of/IN
apoptosis/NN
./.
====================
Aberrant/JJ
activation/NN
of/IN
PI3K/Akt/NN
signaling/NN
has/VBZ
been/VBN
associated/VBN
with/IN
the/DT
development/NN
and/CC
progression/NN
of/IN
many/JJ
cancers/NNS
[/(
35/CD
]/)
,/,
making/VBG
this/DT
pathway/NN
an/DT
attractive/JJ
target/NN
for/IN
therapeutic/JJ
strategies/NNS
./.
====================
The/DT
increase/NN
in/IN
p-Akt/NN
level/NN
in/IN
breast/NN
tumor/NN
samples/NNS
correlates/VBZ
with/IN
a/DT
poor/JJ
prognosis/NN
[/(
36/CD
,/,
37/CD
]/)
and/CC
predicts/VBZ
a/DT
worse/JJ
outcome/NN
among/IN
endocrine-treated/JJ
patients/NNS
[/(
38/CD
]/)
./.
====================
The/DT
major/JJ
inhibitor/NN
of/IN
Akt/NN
is/VBZ
the/DT
dual-specificity/JJ
protein/NN
and/CC
lipid/NN
phosphatase/NN
,/,
phosphatase/NN
tensin/NN
homolog/NN
deleted/VBN
on/IN
chromosome/NN
10/CD
(/(
PTEN/NN
)/)
that/WDT
counteracts/VBZ
the/DT
PI3K-dependent/JJ
Akt/NN
activation/NN
by/IN
dephosphorylating/VBG
the/DT
D3/NN
position/NN
of/IN
PIP3/NN
[/(
39/CD
]/)
./.
====================
PTEN/NN
activity/NN
is/VBZ
frequently/RB
lost/VBD
by/IN
mutations/NNS
,/,
deletions/NNS
or/CC
promoter/NN
methylation/NN
silencing/NN
in/IN
many/JJ
primary/JJ
and/CC
metastatic/JJ
human/JJ
cancers/NNS
[/(
40/CD
,/,
41/CD
]/)
./.
====================
The/DT
inhibition/NN
of/IN
PI3K/Akt/NN
and/CC
activation/NN
of/IN
the/DT
PTEN/NN
pathway/NN
constitute/VBP
a/DT
good/JJ
strategy/NN
in/IN
the/DT
prevention/NN
of/IN
cancer/NN
./.
====================
The/DT
recent/JJ
findings/NNS
of/IN
Karkare/JJ
et/FW
al/JJ
./.
====================
[/(
42/CD
]/)
proved/VBD
that/IN
nimbolide/NN
suppresses/VBZ
glioblastoma/NN
viability/NN
and/CC
detains/VBZ
tumor/NN
growth/NN
by/IN
inhibiting/VBG
CDK4/6/NN
activity/NN
,/,
leading/VBG
to/TO
retinoblastoma/NN
hypophosphorylation/NN
and/CC
cell/NN
cycle/NN
arrest/NN
and/CC
by/IN
inhibiting/VBG
growth/NN
factor/NN
pathways/NNS
that/WDT
are/VBP
hyperactivated/VBN
in/IN
glioblastoma/NN
,/,
including/VBG
the/DT
PI3K-Akt/NN
,/,
MAPK/NN
,/,
and/CC
JAK-STAT/NN
pathways/NNS
[/(
42/CD
]/)
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
decreased/VBD
IGF-IRβ/NN
expression/NN
and/CC
increased/VBD
IGFBP-3/NN
expression/NN
are/VBP
observed/VBN
in/IN
nimbolide-treated/JJ
breast/NN
cancer/NN
cells/NNS
./.
====================
The/DT
protein/NN
expression/NN
of/IN
the/DT
IGF/NN
signaling/NN
molecules/NNS
IRS-2/NN
,/,
PI3K/NN
,/,
pAkt/NN
,/,
Ras/NN
,/,
Raf/NN
,/,
MEK/NN
,/,
and/CC
MAPK/NN
was/VBD
significantly/RB
decreased/VBD
in/IN
nimbolide-treated/JJ
cells/NNS
./.
====================
This/DT
is/VBZ
further/RBR
supported/VBD
by/IN
a/DT
significant/JJ
increase/NN
in/IN
the/DT
protein/NN
expression/NN
of/IN
PTEN/NN
upon/IN
nimbolide/NN
treatment/NN
in/IN
breast/NN
cancer/NN
cell/NN
lines/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Thereby/RB
,/,
nimbolide/NN
inhibits/VBZ
the/DT
cell/NN
survival/NN
and/CC
proliferation/NN
of/IN
breast/NN
cancer/NN
and/CC
prostate/NN
cancer/NN
cells/NNS
[/(
19/CD
,/,
43/CD
]/)
./.
====================
NF-κB/NN
comprises/VBZ
a/DT
family/NN
of/IN
transcription/NN
factors/NNS
involved/VBN
in/IN
the/DT
regulation/NN
of/IN
a/DT
wide/JJ
variety/NN
of/IN
biological/JJ
responses/NNS
./.
====================
NF-κB/NN
has/VBZ
a/DT
well-known/JJ
function/NN
in/IN
the/DT
regulation/NN
of/IN
immune/JJ
responses/NNS
and/CC
inflammation/NN
,/,
but/CC
growing/VBG
evidence/NN
supports/VBZ
a/DT
major/JJ
role/NN
in/IN
oncogenesis/NN
./.
====================
NF-κB/NN
regulates/VBZ
the/DT
expression/NN
of/IN
genes/NNS
involved/VBN
in/IN
many/JJ
processes/NNS
that/DT
play/VBP
a/DT
key/JJ
role/NN
in/IN
the/DT
development/NN
and/CC
progression/NN
of/IN
cancer/NN
,/,
such/JJ
as/IN
proliferation/NN
,/,
migration/NN
,/,
and/CC
apoptosis/NN
[/(
44/CD
,/,
45/CD
]/)
./.
====================
This/DT
transcription/NN
factor/NN
is/VBZ
localized/VBN
in/IN
the/DT
cytosol/NN
and/CC
is/VBZ
blocked/VBN
by/IN
Iκb/NN
./.
====================
Activation/NN
of/IN
NF-κB/NN
may/MD
result/VB
from/IN
different/JJ
signaling/NN
pathways/NNS
triggered/VBN
by/IN
a/DT
variety/NN
of/IN
cytokines/NNS
,/,
growth/NN
factors/NNS
,/,
and/CC
tyrosine/NN
kinases/NNS
[/(
44/CD
]/)
./.
====================
Recently/RB
,/,
it/PRP
was/VBD
studied/VBN
that/DT
nimbolide/NN
exerts/VBZ
potent/JJ
anticancer/JJ
effects/NNS
in/IN
HepG2/NN
cells/NNS
by/IN
inhibiting/VBG
NF-κB/NN
activation/NN
and/CC
its/PRP$
downstream/JJ
events/NNS
,/,
such/JJ
as/IN
activation/NN
of/IN
the/DT
Wnt/β-catenin/NN
pathway/NN
and/CC
apoptosis/NN
evasion/NN
./.
====================
Inhibitors/NNS
of/IN
NF-κB/NN
which/WDT
can/MD
block/VB
several/JJ
signalling/NN
pathway/NN
,/,
have/VBP
developed/VBN
as/IN
a/DT
successful/JJ
candidates/NNS
for/IN
novel/JJ
anti-cancer/JJ
regimens/NNS
./.
====================
Thus/RB
,/,
nimbolide/NN
,/,
by/IN
targeting/VBG
multiple/JJ
components/NNS
of/IN
the/DT
NF-κB/NN
signaling/NN
pathway/NN
to/TO
inhibit/VB
tumor/NN
progression/NN
,/,
is/VBZ
a/DT
promising/JJ
agent/NN
for/IN
cancer/NN
prevention/NN
and/CC
therapy/NN
[/(
17/CD
]/)
./.
====================
Gupta/NN
et/FW
al/JJ
./.
====================
[/(
16/CD
]/)
found/VBN
that/IN
suppression/NN
of/IN
NF-κB/NN
activation/NN
by/IN
nimbolide/NN
was/VBD
caused/VBN
by/IN
inhibition/NN
of/IN
IKK/NN
,/,
which/WDT
led/VBD
to/TO
suppression/NN
of/IN
IκB/NN
phosphorylation/NN
and/CC
degradation/NN
,/,
nuclear/JJ
translocation/NN
,/,
DNA/NN
binding/NN
,/,
and/CC
gene/NN
transcription/NN
in/IN
myeloid/JJ
and/CC
leukemic/JJ
cells/NNS
./.
====================
Nimbolide/NN
significantly/RB
decreased/VBD
the/DT
protein/NN
expression/NN
of/IN
IKKα/NN
,/,
IKKβ/NN
,/,
and/CC
NF-κB/NN
in/IN
breast/NN
cancer/NN
cell/NN
lines/NNS
[/(
46/CD
]/)
./.
====================
Metastasis/NN
is/VBZ
the/DT
process/NN
by/IN
which/WDT
a/DT
cancer/NN
cell/NN
leaves/NNS
the/DT
primary/JJ
tumor/NN
,/,
travels/VBZ
to/TO
a/DT
distant/JJ
site/NN
via/IN
the/DT
circulatory/JJ
system/NN
,/,
and/CC
begins/VBZ
a/DT
secondary/JJ
tumor/NN
./.
====================
In/IN
order/NN
to/TO
metastasize/VB
,/,
cancer/NN
cells/NNS
must/MD
invade/VB
through/IN
the/DT
basement/JJ
membrane/NN
and/CC
the/DT
extracellular/JJ
matrix/NN
(/(
ECM/NN
)/)
./.
====================
Proteolysis/NN
of/IN
the/DT
ECM/NN
is/VBZ
an/DT
important/JJ
step/NN
in/IN
metastasis/NN
,/,
and/CC
the/DT
process/NN
is/VBZ
associated/VBN
with/IN
the/DT
upregulated/VBN
production/NN
and/CC
activity/NN
of/IN
several/JJ
ECM-degrading/JJ
proteases/NNS
./.
====================
The/DT
matrix/NN
metalloproteinases/NNS
(/(
MMPs/NNS
)/)
constitute/VBP
a/DT
family/NN
of/IN
structurally/RB
related/JJ
,/,
zinc-dependent/JJ
endopeptidases/NNS
that/DT
are/VBP
capable/JJ
of/IN
degrading/VBG
the/DT
protein/NN
components/NNS
of/IN
the/DT
ECM/NN
and/CC
basement/JJ
membrane/NN
and/CC
release/NN
growth/NN
factors/NNS
from/IN
ECM/NN
stores/NNS
[/(
47/CD
,/,
48/CD
]/)
./.
====================
MMP/NN
activity/NN
is/VBZ
regulated/VBN
by/IN
specific/JJ
inhibitors/NNS
,/,
the/DT
tissue/NN
inhibitors/NNS
of/IN
MMP/NN
(/(
TIMPs/NNS
)/)
./.
====================
Activation/NN
of/IN
chemokines/NNS
and/CC
the/DT
urokinase/NN
plasminogen/NN
activator/NN
(/(
uPA/NN
)/)
/uPA/NN
receptor/NN
(/(
uPAR/NN
)/)
system/NN
is/VBZ
also/RB
a/DT
central/JJ
mediator/NN
of/IN
tumor-cell/NN
migration/NN
and/CC
invasion/NN
,/,
and/CC
IGF-I/NN
signaling/NN
can/MD
influence/VB
the/DT
uPAR/NN
pathway/NN
./.
====================
Chemokines/NNS
are/VBP
chemotactic/JJ
cytokines/NNS
that/WDT
cause/VBP
the/DT
directed/JJ
migration/NN
of/IN
leukocytes/NNS
and/CC
are/VBP
induced/VBN
by/IN
inflammatory/JJ
cytokines/NNS
,/,
growth/NN
factors/NNS
,/,
and/CC
pathogenic/JJ
stimuli/NNS
./.
====================
Chemokine/NN
signaling/NN
results/NNS
in/IN
the/DT
transcription/NN
of/IN
target/NN
genes/NNS
that/WDT
are/VBP
involved/VBN
in/IN
cell/NN
invasion/NN
,/,
motility/NN
,/,
and/CC
survival/NN
./.
====================
The/DT
upregulation/NN
of/IN
chemokine/NN
molecules/NNS
in/IN
tumor/NN
biology/NN
as/IN
compared/VBN
with/IN
``/NN
normal/JJ
''/JJ
cells/NNS
confers/VBZ
chemokines/NNS
as/IN
``/RB
a/DT
magic/JJ
bullet/NN
,/,
''/NNP
as/IN
targeting/VBG
them/PRP
can/MD
potentially/RB
hit/VBP
cancer/NN
cells/NNS
and/CC
their/PRP$
metastasis/NN
,/,
leaving/VBG
non-affected/JJ
cells/NNS
unharmed/VBD
[/(
49/CD
]/)
./.
====================
The/DT
expression/NN
of/IN
the/DT
chemokines/NNS
CCL2/NN
,/,
CXCL12/NN
,/,
and/CC
CXCL8/NN
and/CC
their/PRP$
receptors/NNS
CCR2/NN
,/,
CXCR1/NN
,/,
CXCR2/NN
,/,
and/CC
CXCR4/NN
is/VBZ
significantly/RB
decreased/VBD
in/IN
nimbolide-treated/JJ
breast/NN
cancer/NN
cell/NN
lines/NNS
[/(
46/CD
]/)
./.
====================
uPA/NN
is/VBZ
a/DT
serine/NN
protease/NN
that/DT
is/VBZ
involved/VBN
in/IN
cancer/NN
progression/NN
,/,
mainly/RB
invasion/NN
and/CC
metastasis/NN
[/(
50/CD
]/)
./.
====================
uPA/NN
can/MD
be/VB
observed/VBN
as/IN
a/DT
multifunctional/JJ
protein/NN
that/WDT
is/VBZ
involved/VBN
in/IN
both/CC
proteolysis/NN
and/CC
signal/NN
transduction/NN
[/(
51/CD
]/)
./.
====================
Recently/RB
,/,
nimbolide/NN
has/VBZ
been/VBN
shown/VBN
to/TO
interfere/VB
with/IN
the/DT
expression/NN
of/IN
NF-κB-regulated/JJ
proteins/NNS
,/,
like/IN
Bcl-2/NN
,/,
cyclooxygenase/NN
2/CD
,/,
MMP-9/NN
,/,
and/CC
VEGF/NN
,/,
by/IN
inhibiting/VBG
IKK/NN
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
likely/JJ
that/IN
nimbolide/NN
will/MD
interfere/VB
with/IN
cell/NN
migration/NN
invasion/NN
and/CC
angiogenesis/NN
[/(
29/CD
]/)
./.
====================
The/DT
neem/NN
limonoids/NNS
azadirachtin/NN
and/CC
nimbolide/NN
inhibit/VBP
hamster/NN
cheek/NN
pouch/JJ
carcinogenesis/NN
by/IN
prevention/NN
of/IN
procarcinogen/NN
activation/NN
and/CC
oxidative/JJ
DNA/NN
damage/NN
,/,
upregulation/NN
of/IN
antioxidants/NNS
and/CC
carcinogen/NN
detoxification/NN
enzymes/NNS
,/,
and/CC
inhibition/NN
of/IN
tumor/NN
invasion/NN
and/CC
angiogenesis/NN
[/(
24/CD
]/)
./.
====================
The/DT
protein/NN
expression/NN
of/IN
MMP-2/NN
and/CC
-9/CD
is/VBZ
significantly/RB
decreased/VBD
,/,
and/CC
TIMP-2/NN
expression/NN
is/VBZ
increased/VBN
in/IN
nimbolide-treated/JJ
breast/NN
cancer/NN
cells/NNS
[/(
46/CD
]/)
./.
====================
Other/JJ
studies/NNS
also/RB
reported/VBD
that/IN
the/DT
protein/NN
expression/NN
and/CC
activity/NN
of/IN
MMP-2/NN
and/CC
-9/CD
were/VBD
significantly/RB
decreased/VBD
in/IN
myeloid/JJ
leukemia/NN
cell/NN
lines/NNS
[/(
16/CD
]/)
and/CC
colon/NN
cancer/NN
cells/NNS
[/(
29/CD
]/)
./.
====================
Limonoid-treated/JJ
xenografts/NNS
exhibited/VBD
significant/JJ
down-regulation/NN
in/IN
the/DT
expression/NN
of/IN
proteins/NNS
involved/VBN
in/IN
tumor/NN
cell/NN
survival/NN
(/(
Bcl-2/NN
,/,
Bcl-xL/NN
,/,
c-IAP-1/NN
,/,
survivin/NN
,/,
and/CC
Mcl-1/NN
)/)
,/,
proliferation/NN
(/(
c-Myc/NN
and/CC
cyclin/NN
D1/NN
)/)
,/,
invasion/NN
(/(
MMP-9/NN
,/,
intercellular/JJ
adhesion/NN
molecule/NN
1/CD
)/)
,/,
metastasis/NN
(/(
CXCR4/NN
)/)
,/,
and/CC
angiogenesis/NN
(/(
VEGF/NN
)/)
[/(
26/CD
]/)
./.
====================
The/DT
migration/NN
and/CC
invasive/JJ
potential/JJ
of/IN
the/DT
MCF-7/NN
and/CC
MDA-MB-231/NN
cell/NN
lines/NNS
were/VBD
considerably/RB
suppressed/VBD
upon/IN
nimbolide/NN
treatment/NN
./.
====================
The/DT
results/NNS
showed/VBD
that/IN
nimbolide/NN
downregulated/VBD
the/DT
expression/NN
of/IN
uPA/NN
,/,
uPAR/NN
,/,
chemokines/NNS
,/,
phopho-epidermal/JJ
growth/NN
factor/NN
receptor/NN
,/,
vascular/JJ
endothelial/JJ
growth/NN
factor/NN
,/,
NF-κB/NN
,/,
IKKα/NN
,/,
IKKβ/NN
,/,
MMP-2/NN
,/,
and/CC
MMP-9/NN
and/CC
upregulated/VBD
the/DT
expression/NN
of/IN
TIMP-2/NN
,/,
suggesting/VBG
that/IN
nimbolide/NN
inhibits/VBZ
angiogenesis/NN
and/CC
metastasis/NN
of/IN
breast/NN
cancer/NN
[/(
46/CD
]/)
./.
====================
The/DT
loss/NN
of/IN
the/DT
ability/NN
to/TO
regulate/VB
the/DT
cell-cycle/JJ
is/VBZ
characteristic/JJ
of/IN
cancer/NN
cells/NNS
and/CC
results/VBZ
in/IN
uncontrollable/JJ
proliferation/NN
./.
====================
Processing/VBG
cells/NNS
through/IN
the/DT
first/JJ
gap/NN
(/(
G/NN
)/)
phase/NN
of/IN
the/DT
cell/NN
cycle/NN
is/VBZ
a/DT
step/JJ
that/IN
is/VBZ
frequently/RB
disordered/VBN
in/IN
cancer/NN
[/(
52/CD
]/)
./.
====================
Nimbolide/NN
has/VBZ
been/VBN
investigated/VBN
in/IN
different/JJ
studies/NNS
for/IN
its/PRP$
ability/NN
to/TO
mediate/VB
cell/NN
cycle/NN
arrest/NN
./.
====================
In/IN
many/JJ
in/IN
vitro/FW
and/CC
in/IN
vivo/FW
studies/NNS
,/,
nimbolide/NN
has/VBZ
shown/VBN
cell/NN
cycle-regulatory/JJ
effects/NNS
[/(
18/CD
,/,
25/CD
,/,
53/CD
,/,
54/CD
]/)
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
nimbolide/NN
inhibits/VBZ
cell/NN
proliferation/NN
by/IN
interfering/VBG
with/IN
cell/NN
cycle/NN
kinetics/NNS
by/IN
inducing/VBG
G0/G1/NN
and/CC
S/NN
phase/NN
arrest/NN
,/,
primarily/RB
caused/VBD
through/IN
the/DT
repression/NN
of/IN
cyclin/NN
A/cyclin/NN
D1/NN
[/(
16/CD
,/,
54/CD
,/,
55/CD
]/)
./.
====================
In/IN
another/DT
interesting/JJ
molecular/JJ
study/NN
,/,
a/DT
Japanese/JJ
group/NN
has/VBZ
proved/VBN
that/IN
nimbolide/NN
,/,
a/DT
triterpenoid/JJ
present/JJ
in/IN
certain/JJ
edible/JJ
parts/NNS
of/IN
A./NNP
indica/NNP
,/,
arrested/VBN
HT-29/NN
cells/NNS
in/IN
the/DT
G2/M/NN
and/CC
G0/G1/NN
stages/NNS
apparently/RB
through/IN
upregulation/NN
of/IN
p21/NN
,/,
which/WDT
is/VBZ
a/DT
well-known/JJ
downstream/JJ
effector/NN
of/IN
the/DT
p53/NN
./.
====================
p53/NN
is/VBZ
a/DT
very/RB
important/JJ
anticancer/JJ
protein/NN
that/WDT
regulates/VBZ
a/DT
large/JJ
number/NN
of/IN
genes/NNS
that/WDT
are/VBP
involved/VBN
in/IN
cancer/NN
progression/NN
./.
====================
Nimbolide/NN
has/VBZ
also/RB
been/VBN
shown/VBN
to/TO
upregulate/VB
cyclin/NN
D2/NN
and/CC
CDK2/NN
and/CC
to/TO
suppress/VB
the/DT
expression/NN
of/IN
cyclin/NN
A/DT
,/,
cyclin/NN
E/NN
,/,
CDK2/NN
,/,
and/CC
Rad17/NN
at/IN
the/DT
same/JJ
time/NN
[/(
53/CD
]/)
./.
====================
Flow/NN
cytometric/JJ
analysis/NN
of/IN
U937/NN
cells/NNS
showed/VBD
that/IN
nimbolide/NN
treatment/NN
(/(
1-2.5/CD
µM/NN
)/)
resulted/VBD
in/IN
cell/NN
cycle/NN
disruption/NN
by/IN
decreasing/VBG
the/DT
number/NN
of/IN
cells/NNS
in/IN
G0/G1/NN
phase/NN
,/,
with/IN
initial/JJ
increases/VBZ
in/IN
S/NN
and/CC
G2/M/NN
phases/NNS
./.
====================
It/PRP
is/VBZ
shown/VBN
that/IN
nimbolide/NN
can/MD
affect/VB
cell/NN
cycle/NN
progression/NN
and/CC
induce/VBP
apoptosis/NN
in/IN
colon/NN
cancer/NN
,/,
oral/JJ
carcinoma/NN
,/,
and/CC
cervical/JJ
cancer/NN
[/(
18/CD
,/,
25/CD
,/,
55/CD
]/)
./.
====================
Nimbolide/DT
significantly/RB
suppressed/VBD
the/DT
viability/NN
of/IN
HeLa/NN
cells/NNS
in/IN
a/DT
dose-dependent/JJ
manner/NN
by/IN
inducing/VBG
cell/NN
cycle/NN
arrest/NN
at/IN
G0/G1/NN
phase/NN
,/,
accompanied/VBN
by/IN
p21/NN
accumulation/NN
and/CC
down-regulation/NN
of/IN
the/DT
cell/NN
cycle/NN
regulatory/JJ
proteins/NNS
cyclin/NN
B/NN
,/,
cyclin/NN
D1/NN
,/,
and/CC
proliferating/VBG
cell/NN
nuclear/JJ
antigen/NN
(/(
PCNA/NN
)/)
[/(
55/CD
]/)
./.
====================
Nimbolide/NN
treatment/NN
results/VBZ
in/IN
the/DT
accumulation/NN
of/IN
cells/NNS
in/IN
G0/G1/NN
phase/NN
and/CC
decreased/VBD
in/IN
S-phase/NN
by/IN
up/RB
regulating/VBG
p21/NN
and/CC
downregulating/VBG
the/DT
cell/NN
cycle-regulatory/JJ
proteins/NNS
cyclins/NNS
and/CC
PCNA/NN
./.
====================
Cyclin/NN
D1/NN
is/VBZ
known/VBN
as/IN
a/DT
proto-oncogene/NN
whose/WP$
gene/NN
amplification/NN
and/CC
protein/NN
overexpression/NN
of/IN
which/WDT
are/VBP
frequently/RB
observed/VBN
in/IN
tumor/NN
cells/NNS
./.
====================
The/DT
activated/VBN
cyclin/NN
D1/CDK4/NN
and/CC
cyclin/NN
D1/CDK6/NN
complex/NN
phosphorylates/VBZ
the/DT
retinoblastoma/NN
protein/NN
to/TO
induce/VB
the/DT
expression/NN
of/IN
target/NN
genes/NNS
essential/JJ
for/IN
S/NN
phase/NN
entry/NN
,/,
facilitating/VBG
the/DT
progression/NN
from/IN
G1/NN
to/TO
S/NN
phase/NN
[/(
56/CD
]/)
./.
====================
Cyclin/NN
B1/NN
is/VBZ
a/DT
G2/mitotic-specific/JJ
protein/NN
that/WDT
plays/VBZ
a/DT
role/NN
in/IN
the/DT
initiation/NN
of/IN
mitosis/NN
and/CC
tumorigenesis/NN
[/(
57/CD
]/)
./.
====================
It/PRP
was/VBD
reported/VBN
that/IN
cyclin/NN
B1/NN
depletion/NN
inhibits/VBZ
proliferation/NN
and/CC
induces/VBZ
apoptosis/NN
in/IN
human/JJ
tumor/NN
cells/NNS
[/(
57/CD
]/)
./.
====================
Nimbolide/NN
treatment/NN
decreases/VBZ
cyclin/NN
(/(
A1/NN
,/,
B1/NN
,/,
C/NN
,/,
D1/NN
,/,
and/CC
E1/NN
)/)
expression/NN
in/IN
breast/NN
cancer/NN
cells/NNS
./.
====================
p21Waf1/Cip1/NN
,/,
originally/RB
identified/VBN
as/IN
an/DT
inhibitor/NN
of/IN
the/DT
cyclin/CDK/NN
complexes/NNS
,/,
has/VBZ
also/RB
been/VBN
shown/VBN
to/TO
have/VB
a/DT
role/NN
as/IN
an/DT
adaptor/NN
protein/NN
that/WDT
assembles/NNS
and/CC
promotes/VBZ
the/DT
kinase/NN
activity/NN
of/IN
cyclin/NN
D/CDK4/NN
complexes/NNS
[/(
58/CD
]/)
./.
====================
The/DT
level/NN
of/IN
p21/NN
was/VBD
significantly/RB
increased/VBD
in/IN
nimbolide-treated/JJ
breast/NN
cancer/NN
cell/NN
lines/NNS
./.
====================
PCNA/NN
,/,
a/DT
cofactor/NN
for/IN
DNA/NN
polymerase/NN
δ/NN
,/,
plays/VBZ
a/DT
central/JJ
role/NN
in/IN
cell/NN
cycle/NN
progression/NN
[/(
59/CD
]/)
./.
====================
PCNA/NN
is/VBZ
involved/VBN
in/IN
a/DT
wide/JJ
range/NN
of/IN
cellular/JJ
functions/NNS
,/,
including/VBG
DNA/NN
replication/NN
,/,
repair/NN
,/,
and/CC
epigenetic/JJ
maintenance/NN
,/,
and/CC
is/VBZ
often/RB
used/VBN
as/IN
a/DT
diagnostic/JJ
and/CC
prognostic/JJ
marker/NN
./.
====================
The/DT
protein/NN
expression/NN
of/IN
PCNA/NN
is/VBZ
decreased/VBN
in/IN
nimbolide-treated/JJ
breast/NN
cancer/NN
cells/NNS
[/(
19/CD
]/)
./.
====================
Nimbolide/NN
directly/RB
inhibited/VBD
CDK4/CDK6/NN
kinase/NN
activity/NN
,/,
leading/VBG
to/TO
hypophosphorylation/NN
of/IN
the/DT
retinoblastoma/NN
protein/NN
,/,
cell/NN
cycle/NN
arrest/NN
at/IN
G1-S/NN
,/,
and/CC
cell/NN
death/NN
[/(
42/CD
]/)
./.
====================
In/IN
animal/NN
tumor/NN
models/NNS
,/,
nimbolide/NN
(/(
100/CD
µg/kg/NN
)/)
has/VBZ
been/VBN
shown/VBN
to/TO
exhibit/VB
chemopreventive/JJ
activity/NN
against/IN
7,12-dimethylbenzanthracene/JJ
(/(
DMBA/NN
)/)
3-induced/JJ
hamster/NN
buccal/JJ
pouch/JJ
carcinogenesis/NN
by/IN
downregulating/VBG
proteins/NNS
involved/VBN
in/IN
cell/NN
cycle/NN
progression/NN
and/CC
transduce/VBP
apoptosis/NN
by/IN
both/DT
the/DT
intrinsic/JJ
and/CC
extrinsic/JJ
pathways/NNS
[/(
25/CD
]/)
./.
====================
Apoptosis/NN
,/,
or/CC
programmed/VBN
cell/NN
death/NN
,/,
is/VBZ
essential/JJ
for/IN
the/DT
maintenance/NN
of/IN
development/NN
and/CC
homeostasis/NN
of/IN
multi-cellular/JJ
organisms/NNS
by/IN
eliminating/VBG
superfluous/JJ
or/CC
unwanted/JJ
cells/NNS
./.
====================
Any/DT
alteration/NN
or/CC
change/NN
in/IN
the/DT
normal/JJ
process/NN
of/IN
apoptosis/NN
may/MD
increase/VB
cell/NN
survival/NN
and/CC
support/VBP
tumor/NN
development/NN
and/CC
progression/NN
[/(
60/CD
]/)
./.
====================
The/DT
extrinsic/JJ
and/CC
intrinsic/JJ
pathways/NNS
represent/VBP
the/DT
two/CD
major/JJ
well-studied/JJ
apoptotic/JJ
processes/NNS
./.
====================
Inefficient/JJ
apoptosis/NN
is/VBZ
considered/VBN
one/CD
of/IN
the/DT
hallmarks/NNS
of/IN
tumorigenicity/NN
[/(
61/CD
]/)
./.
====================
Moreover/RB
,/,
induction/NN
of/IN
apoptosis/NN
is/VBZ
an/DT
important/JJ
target/NN
for/IN
cancer/NN
therapy/NN
[/(
62/CD
]/)
./.
====================
The/DT
extrinsic/JJ
pathway/NN
is/VBZ
initiated/VBN
by/IN
cell/NN
surface-expressed/VBD
death/NN
receptors/NNS
of/IN
the/DT
tumor/NN
necrosis/NN
factor/NN
superfamily/NN
./.
====================
One/CD
of/IN
the/DT
central/JJ
pathways/NNS
of/IN
apoptosis/NN
is/VBZ
initiated/VBN
by/IN
cytokines/NNS
,/,
such/JJ
as/IN
tumor/NN
necrosis/NN
factor-α/NN
,/,
Fas/NN
ligand/NN
(/(
FasL/NN
)/)
,/,
and/CC
tumor/NN
necrosis/NN
factor-α-related/JJ
apoptosis-inducing/VBG
ligand/NN
(/(
TRAIL/NN
)/)
[/(
63/CD
]/)
./.
====================
The/DT
intrinsic/JJ
pathway/NN
is/VBZ
initiated/VBN
by/IN
anticancer/JJ
drugs/NNS
,/,
growth/NN
factor/NN
withdrawal/NN
,/,
or/CC
hypoxia/NN
or/CC
via/IN
induction/NN
of/IN
oncogenes/NNS
./.
====================
These/DT
stimuli/NNS
induce/VBP
permeabilization/NN
of/IN
the/DT
outer/NN
mitochondrial/JJ
membrane/NN
and/CC
activate/VBP
the/DT
mitochondrial/JJ
pathway/NN
[/(
64/CD
]/)
./.
====================
Caspases/NNS
are/VBP
a/DT
family/NN
of/IN
evolutionarily/RB
conserved/VBN
cysteine/NN
proteases/NNS
that/DT
play/VBP
a/DT
essential/JJ
role/NN
in/IN
the/DT
majority/NN
of/IN
apoptotic/JJ
pathways/NNS
./.
====================
Death/IN
signals/NNS
activate/VBP
the/DT
proteolytic/JJ
cascade/NN
of/IN
caspases/NNS
through/IN
two/CD
main/JJ
pathways/NNS
:/:
an/DT
extrinsic/JJ
and/CC
intrinsic/JJ
pathway/NN
[/(
65/CD
]/)
./.
====================
Both/DT
pathways/NNS
converge/VBP
to/TO
the/DT
activation/NN
of/IN
caspase-3/NN
,/,
the/DT
closer/NN
homolog/NN
of/IN
Caenorhabditis/NN
elegans/NNS
CED-3/NN
[/(
66/CD
]/)
./.
====================
Caspase-3/NN
activates/VBZ
downstream/JJ
enzymes/NNS
of/IN
the/DT
caspase/NN
family/NN
and/CC
contributes/VBZ
with/IN
them/PRP
to/TO
generate/VB
the/DT
typical/JJ
apoptotic/JJ
cell/NN
death/NN
phenotype/NN
[/(
67/CD
]/)
./.
====================
Harish/JJ
Kumar/JJ
et/FW
al/JJ
./.
====================
[/(
25/CD
]/)
reported/VBD
that/IN
nimbolide/NN
transduces/VBZ
apoptosis/NN
by/IN
both/CC
the/DT
intrinsic/JJ
and/CC
extrinsic/JJ
pathways/NNS
in/IN
DMBA-induced/JJ
hamster/NN
buccal/JJ
pouch/JJ
carcinogenesis/NN
./.
====================
Working/VBG
on/IN
the/DT
choriocarcinoma/NN
(/(
BeWo/NNP
)/)
cells/NNS
,/,
have/VBP
shown/VBN
that/IN
nimbolide/NN
,/,
induces/VBZ
apoptosis/NN
through/IN
engagement/NN
of/IN
the/DT
mitochondrial/JJ
pathway/NN
./.
====================
The/DT
involvement/NN
of/IN
this/DT
pathway/NN
is/VBZ
based/VBN
on/IN
the/DT
observation/NN
that/IN
nimbolide/NN
mediates/VBZ
the/DT
upregulation/NN
of/IN
Apaf1/NN
and/CC
a/DT
caspase-3/NN
and/CC
decrease/NN
in/IN
the/DT
Bcl2/Bax/NN
ratio/NN
[/(
54/CD
]/)
./.
====================
Nimbolide/NN
sensitizes/VBZ
human/JJ
colon/NN
cancer/NN
cell/NN
lines/NNS
(/(
HCT-116/NN
and/CC
HT-29/NN
)/)
to/TO
TRAIL/NN
through/IN
reactive/JJ
oxygen/NN
species-/NN
and/CC
Erk-dependent/JJ
up-regulation/NN
of/IN
death/NN
receptors/NNS
,/,
p53/NN
,/,
and/CC
Bax/NN
./.
====================
A/DT
normal/JJ
breast/NN
cell/NN
line/NN
(/(
MCF-10A/NN
)/)
and/CC
breast/NN
cancer/NN
cell/NN
lines/NNS
(/(
MCF-7/NN
)/)
were/VBD
treated/VBN
with/IN
nimbolide/NN
(/(
1-5/CD
µM/NN
)/)
for/IN
6/CD
h/NN
,/,
followed/VBN
by/IN
TRAIL/NN
for/IN
24/CD
h./FW
The/DT
results/NNS
indicated/VBD
that/IN
whereas/IN
nimbolide/NN
and/CC
TRAIL/NN
alone/RB
were/VBD
minimally/RB
effective/JJ
in/IN
inducing/VBG
apoptosis/NN
in/IN
MCF-7/NN
cells/NNS
,/,
the/DT
combination/NN
of/IN
both/DT
enhanced/VBN
the/DT
number/NN
of/IN
apoptotic/JJ
cells/NNS
to/TO
42/CD
%/NN
./.
====================
Conversely/RB
,/,
the/DT
combination/NN
of/IN
nimbolide/NN
and/CC
TRAIL/NN
was/VBD
unable/JJ
to/TO
evoke/VB
apoptosis/NN
in/IN
the/DT
normal/JJ
breast/NN
cell/NN
line/NN
./.
====================
The/DT
results/NNS
showed/VBD
a/DT
lack/NN
of/IN
DR5/NN
and/CC
DR4/NN
induction/NN
in/IN
MCF-10A/NN
cells/NNS
by/IN
nimbolide/NN
,/,
whereas/IN
a/DT
dose-dependent/JJ
induction/NN
of/IN
these/DT
receptors/NNS
was/VBD
observed/VBN
in/IN
MCF-7/NN
cells/NNS
[/(
68/CD
]/)
./.
====================
The/DT
decreased/VBN
expression/NN
of/IN
Bcl-2/NN
and/CC
increased/VBD
expression/NN
of/IN
bax/NN
,/,
cytochrome/NN
c/NN
,/,
Smac/NN
,/,
and/CC
caspases/NNS
,/,
together/RB
with/IN
changes/NNS
in/IN
nuclear/JJ
morphology/NN
and/CC
mitochondrial/JJ
transmembrane/JJ
potential/JJ
,/,
seen/VBN
in/IN
nimbolide/NN
treatment/NN
and/CC
inhibition/NN
of/IN
NF-κB/JJ
activation/NN
by/IN
nimbolide/NN
,/,
stimulate/VBP
the/DT
intrinsic/JJ
apoptotic/JJ
pathway/NN
in/IN
HepG2/NN
cells/NNS
[/(
17/CD
]/)
./.
====================
In/IN
another/DT
study/NN
,/,
nimbolide/NN
repressed/VBD
cell/NN
proliferation/NN
by/IN
inhibiting/VBG
the/DT
IGF1/IGF-IR-PI3K/Akt/NN
pathway/NN
and/CC
induced/VBD
apoptosis/NN
through/IN
the/DT
activation/NN
of/IN
both/DT
the/DT
extrinsic/JJ
and/CC
intrinsic/JJ
apoptotic/JJ
pathways/NNS
in/IN
prostate/NN
cancer/NN
cells/NNS
[/(
43/CD
]/)
./.
====================
Nimbolide/DT
also/RB
induced/VBD
apoptosis/NN
in/IN
breast/NN
cancer/NN
cells/NNS
by/IN
upregulating/VBG
pro-apoptotic/JJ
protein/NN
(/(
Bad/NN
,/,
Bax/NN
,/,
FasL/NN
,/,
FADD/NN
,/,
TRAIL/NN
,/,
and/CC
cytochrome/NN
c/NN
)/)
expression/NN
and/CC
down-regulating/VBG
anti-apoptotic/JJ
proteins/NNS
(/(
Bcl-2/NN
,/,
Bcl-xL/NN
,/,
Mcl-1/NN
,/,
and/CC
XIAP-1/NN
)/)
./.
====================
Nimbolide/NN
activates/VBZ
caspase-3/NN
,/,
-8/CD
,/,
and/CC
-9/CD
,/,
which/WDT
favors/VBZ
the/DT
cleavage/NN
of/IN
poly/RB
(/(
ADP/NN
)/)
ribose/NN
polymerase/NN
into/IN
115-/CD
and/CC
85-kDa/JJ
peptides/NNS
,/,
thus/RB
inducing/VBG
apoptosis/NN
in/IN
breast/NN
cancer/NN
cell/NN
lines/NNS
./.
====================
Further/RB
,/,
the/DT
nimbolide-induced/JJ
apoptotic/JJ
cells/NNS
were/VBD
detected/VBN
using/VBG
DAPI/NN
and/CC
AO/EtBr/NN
dual/JJ
staining/NN
./.
====================
After/IN
treatment/NN
with/IN
nimbolide/NN
,/,
the/DT
cells/NNS
exhibited/VBD
the/DT
typical/JJ
morphological/JJ
changes/NNS
associated/VBN
with/IN
apoptosis/NN
:/:
cell/NN
shrinkage/NN
,/,
nuclear/JJ
condensation/NN
,/,
and/CC
membrane/NN
blebbing/VBG
[/(
30/CD
]/)
./.
====================
Activation/NN
of/IN
caspase-3/NN
,/,
-8/CD
,/,
and/CC
-9/CD
,/,
suggests/VBZ
that/IN
nimbolide/NN
potentiated/VBD
both/CC
the/DT
extrinsic/JJ
and/CC
intrinsic/JJ
pathways/NNS
of/IN
apoptosis/NN
in/IN
human/JJ
breast/NN
and/CC
colon/NN
cancer/NN
cells/NNS
[/(
68/CD
,/,
30/CD
]/)
./.
====================
The/DT
overview/NN
of/IN
all/DT
of/IN
the/DT
signaling/NN
molecules/NNS
modulated/VBN
by/IN
nimbolide/NN
is/VBZ
shown/VBN
in/IN
Fig/NN
./.
====================
4/CD
./.
====================
Cancer/NN
has/VBZ
continually/RB
been/VBN
the/DT
leading/VBG
cause/VBP
of/IN
death/NN
worldwide/NN
for/IN
decades/NNS
./.
====================
Thus/RB
,/,
researchers/NNS
have/VBP
actively/RB
devoted/VBN
themselves/NNS
to/TO
studying/VBG
cancer/NN
therapeutics/NNS
./.
====================
The/DT
present/JJ
mode/NN
of/IN
treatment/NN
based/VBN
on/IN
chemotherapy/NN
and/CC
radiotherapy/NN
is/VBZ
very/RB
expensive/JJ
and/CC
also/RB
exhibits/VBZ
serious/JJ
side/JJ
effects/NNS
in/IN
human/JJ
beings/NNS
./.
====================
Keeping/VBG
in/IN
view/NN
the/DT
significance/NN
of/IN
herbs/RB
,/,
this/DT
review/NN
is/VBZ
written/VBN
to/TO
show/VB
the/DT
role/NN
of/IN
nimbolide/NN
in/IN
the/DT
prevention/NN
of/IN
various/JJ
types/NNS
of/IN
cancer/NN
through/IN
the/DT
activation/NN
or/CC
inactivation/NN
of/IN
various/JJ
signaling/NN
pathways/NNS
./.
====================
These/DT
reported/VBD
features/NNS
,/,
combined/JJ
with/IN
the/DT
absence/NN
of/IN
side/JJ
effects/NNS
and/CC
being/VBG
inexpensive/JJ
and/CC
easy/RB
to/TO
access/VB
,/,
neem/CC
and/CC
its/PRP$
constituent/NN
nimbolide/NN
may/MD
be/VB
proved/VBN
very/RB
effective/JJ
therapeutics/NNS
in/IN
the/DT
management/JJ
of/IN
cancers/NNS
./.
====================
Nimbolide/NN
is/VBZ
a/DT
potential/JJ
chemopreventive/JJ
agent/NN
that/WDT
is/VBZ
able/JJ
to/TO
suppress/VB
multiple/JJ
signaling/NN
pathways/NNS
involved/VBN
in/IN
carcinogenesis/NN
and/CC
hence/RB
is/VBZ
an/DT
attractive/JJ
candidate/NN
for/IN
further/JJ
research/NN
./.
====================
Currently/RB
,/,
nimbolide/NN
is/VBZ
undergoing/VBG
extensive/JJ
research/NN
to/TO
determine/VB
the/DT
dose/NN
efficacy/NN
and/CC
administration/NN
form/VBP
that/DT
could/MD
enhance/VB
its/PRP$
bioavailability/NN
and/CC
chemopreventive/JJ
properties/NNS
./.
====================
How/RB
nimbolide/NN
mediates/VBZ
all/DT
of/IN
these/DT
effects/NNS
is/VBZ
not/RB
completely/RB
understood/VBN
./.
====================
However/RB
,/,
most/JJS
of/IN
the/DT
anticancer/JJ
activities/NNS
assigned/VBN
to/TO
nimbolide/NN
have/VBP
been/VBN
based/VBN
on/IN
in/IN
vitro/FW
studies/NNS
./.
====================
While/IN
in/IN
vitro/FW
studies/NNS
predominantly/RB
established/JJ
the/DT
anti-cancer/JJ
effects/NNS
of/IN
nimbolide/NN
on/IN
cancer/NN
cells/NNS
,/,
its/PRP$
efficiency/NN
in/IN
vivo/FW
has/VBZ
still/RB
to/TO
be/VB
proven/VBN
./.
====================
Structure/NN
of/IN
nimbolide/NN
./.
====================
Molecular/JJ
formula/NN
,/,
C27H30O7/NN
;/:
molecular/JJ
weight/NN
,/,
466.5/CD
;/:
appearance/RB
,/,
white/JJ
to/TO
off-white/VB
solid/JJ
./.
====================
Potential/JJ
mechanisms/NNS
of/IN
cancer/NN
prevention/NN
by/IN
nimbolide/NN
./.
====================
Detailed/JJ
scheme/NN
of/IN
the/DT
growth/NN
factor/NN
signalling/NN
pathways/NNS
targeted/VBN
by/IN
nimbolide/NN
in/IN
cancer/NN
cells/NNS
./.
====================
Nimbolide/NN
strongly/RB
inhibits/VBZ
IGF-IR/NN
and/CC
also/RB
affects/VBZ
downstream/JJ
signalling/NN
via/IN
the/DT
MAPK/NN
(/(
ERK/NN
)/)
and/CC
PI3K/Akt/NN
./.
====================
Transcription/NN
factors/NNS
like/IN
NF-κB/NN
,/,
c-Myc/NN
,/,
and/CC
β-catenin/NN
consequently/RB
can/MD
not/RB
be/VB
activated/VBN
,/,
thus/RB
modulating/VBG
target/NN
gene/NN
expression/NN
./.
====================
As/IN
most/JJS
of/IN
the/DT
target/NN
genes/NNS
are/VBP
implicated/VBN
in/IN
cell/NN
cycle/NN
regulation/NN
and/CC
proliferation/NN
,/,
the/DT
cancer/NN
cells/NNS
are/VBP
finally/RB
blocked/VBD
in/IN
cell/NN
cycle/NN
progression/NN
./.
====================
ERK/NN
,/,
extracellularsignal-regulated/JJ
kinase/NN
;/:
IGF-IR/NN
,/,
insulin-like/JJ
growth/NN
factor/NN
1/CD
receptor/NN
;/:
MAPK/NN
,/,
mitogen-activated/JJ
protein/NN
kinase/NN
;/:
NF-κB/NN
,/,
nuclear/JJ
factor/NN
kappa/NN
B/NN
;/:
PI3K/NN
,/,
phosphoinositide/NN
3-kinase/NN
;/:
PTEN/NN
,/,
phosphatase/NN
tensin/NN
homolog/NN
deleted/VBN
on/IN
chromosome/NN
10/CD
./.
====================
Nimbolide/NN
shows/VBZ
an/DT
important/JJ
role/NN
in/IN
cancer/NN
prevention/NN
via/IN
inhibition/NN
of/IN
cell/NN
survival/NN
,/,
cell/NN
cycle/NN
progression/NN
,/,
invasion/NN
,/,
migration/NN
and/CC
induction/NN
of/IN
apoptosis/NN
./.
====================
The/DT
diverse/JJ
molecular/JJ
targets/NNS
influenced/VBD
by/IN
nimbolide/NN
include/VBP
the/DT
growth/NN
factors/NNS
and/CC
their/PRP$
receptor/NN
,/,
signaling/NN
molecules/NNS
,/,
transcription/NN
factors/NNS
,/,
protein/NN
kinases/NNS
,/,
enzymes/NNS
and/CC
genes/NNS
regulating/VBG
cell/NN
proliferation/NN
and/CC
apoptosis/NN
./.
====================
Red/VBN
down/RB
arrow/NN
indicates/VBZ
that/IN
these/DT
molecules/NNS
are/VBP
down-regulated/VBN
by/IN
nimbolide/NN
,/,
whereas/IN
,/,
green/VBN
up/IN
arrow/NN
indicate/VBP
that/IN
these/DT
molecules/NNS
are/VBP
up-regulated/VBN
by/IN
nimbolide/NN
./.
====================
Bad/RB
,/,
Bcl-2-associated/JJ
death/IN
promoter/RB
;/:
Bax/NNP
,/,
Bcl-2-associated/JJ
X/NN
protein/RB
;/:
Bcl-2/NNP
,/,
B/NN
cell/NN
lymphoma/NN
2/LS
;/:
Bcl-xL/NNP
,/,
B-cell/NNP
lymphoma-extra-large/JJ
;/:
DR-5/RB
,/,
death/IN
receptor-5/RB
;/:
EGFR/NNP
,/,
epidermal/JJ
growth/CC
factor/IN
receptor/NN
;/:
ERK/RB
,/,
extracellular-signal-regulated/JJ
kinase/RB
;/:
FADD/RB
,/,
Fas-associated/JJ
death/IN
domain/RB
;/:
FasL/NNP
,/,
Fatty/RB
acid/RB
synthase/RB
ligand/CC
;/:
ICAM/RB
,/,
Intercellular/JJ
adhesion/NN
molecule/RB
;/:
IGF-1/NNP
,/,
insulin-like/RB
growth/IN
factor/IN
1/LS
;/:
IGFBP-3/RB
,/,
IGF-binding/VBG
protein/RB
3/LS
;/:
IKK/RB
,/,
IkB/NNP
kinase/RB
;/:
IRS/NNP
,/,
insulin/RB
receptor/NN
substrate/RB
;/:
MCL-1/NNP
,/,
myeloid/JJ
cell/NN
leukemia/NN
1/LS
;/:
MMPs/RB
,/,
matrix/RB
metalloproteinases/NNS
;/:
NF-κB/NNP
,/,
nuclear/JJ
factor/NN
kappa/NN
B/NN
;/:
PARP/RB
,/,
poly/RB
(/(
ADP/NNP
)/)
ribose/RB
polymerase/RB
;/:
PCNA/NNP
,/,
proliferating/VBG
cell/RB
nuclear/JJ
antigen/JJ
;/:
PI3K/NNP
,/,
phosphoinositide/RB
3-kinase/RB
;/:
PTEN/NNP
,/,
phosphatase/RB
tensin/RB
homolog/RB
deleted/JJ
on/IN
chromosome/RB
10/CD
;/:
Rb/NNP
,/,
retinoblastoma/RB
;/:
TIMP/NNP
,/,
tissue/RB
inhibitor/IN
of/IN
matrix/DT
metalloproteinase/RB
;/:
TRAIL/RB
,/,
tumor/RB
necrosis/NN
factor/IN
apoptosis/RB
inducing/VBG
ligand/CC
;/:
VEGF/RB
,/,
vascular/JJ
endothelial/JJ
growth/CC
factor/IN
;/:
VEGFR/NNP
,/,
vascular/JJ
endothelial/JJ
growth/CC
factor/IN
receptor/NN
;/:
XIAP/RB
,/,
X-linked/JJ
inhibitor/RB
of/IN
apoptosis/DT
protein/RB
;/:
uPA/RB
,/,
urokinase/RB
plasminogen/RB
antigen/RB
;/:
uPAR/RB
,/,
urokinase/RB
plasminogen/RB
antigen/RB
receptor/NN
./.
====================
